ACCÈS RAPIDE AUX LIENS
Individuals harboring germline mutations in the tumor suppressor gene von Hippel-Lindau (VHL) exhibit an increased susceptibility to a variety of tumors including renal carcinoma, hemangio-blastoma of the central nervous system and pheochromocytoma. The Elongin (SIII) complex has been identified as the functional target of the VHL protein. Elongin (SIII) is a heterotrimer composed of a transcriptional active subunit designated Elongin A and two regulatory subunits designated Elongin B and Elongin C. VHL functions by binding to the Elongin B and C subunits, inhibiting the transcriptional efficacy of the Elongin (SIII) complex.
Informations pour la commande
Nom du produit | Ref. Catalogue | COND. | Prix HT | QTÉ | Favoris | |
Anticorps Elongin A (F-11) | sc-373812 | 200 µg/ml | $316.00 | |||
Elongin A (F-11): m-IgG Fc BP-HRP Kit | sc-540401 | 200 µg Ab; 10 µg BP | $354.00 | |||
Elongin A (F-11): m-IgG2a BP-HRP Kit | sc-546902 | 200 µg Ab; 10 µg BP | $354.00 |